Skip to NavigationSkip to content

INC Research and inVentiv merge to form Syneos Health

Published on 04/01/18 at 05:05pm

With the advent of the new year, INC Research and inVentiv Health have announced they are to merge operations under a new brand identity: Syneos Health. “Purpose-built for modern biopharmaceutical market realities”, Syneos identifies itself as “the only fully integrated, end-to-end biopharmaceutical solutions organisation”, combining the operations of both a CRO and a CCO.   

The new branding, designed by the company’s own agency Addison Whitney, has been specially chosen to represent the new company’s values, with its name Syneos derived from “neo”, signaling a new approach to problem-solving in biopharmaceutical solutions. Syneos’ platform will offer a range of clinical and commercial solutions to speed biopharmaceutical therapies to market, including behavioural insights to accelerate clinical trial recruitment, and therapeutic expertise to better engage stakeholders.

“Syneos Health fully expresses our value proposition – that is, our ability to deliver integrated end-to-end solutions and create new paths for our customers to develop and commercialise their therapies,” explained Alistair Macdonald, Chief Executive Officer of Syneos Health. “Unlike traditional CROs and commercialisation businesses, we are knocking down walls and enabling clinical and commercial experts to work in sync by using the latest technologies, advanced business practices and the advantages of scale. Our Biopharmaceutical Acceleration Model is unique to the industry, and from this ambitious vision, Syneos Health was born.”

Macdonald continued: “As commercialisation experts, we understand the importance a strong brand plays in creating differentiation, conversion and loyalty. Our new identity reinforces our fully integrated business model, positions Syneos Health as a high-value solutions partner, and is designed to attract and retain top talent committed to shortening the distance from lab to life.”

Syneos Health common shares are expected to trade on the Nasdaq Global Select Market under the new ticker symbol “SYNH” by 9 January, 2018. Until then, the company will continue to be listed under INC Research Holdings, Inc. and the symbol “INCR.”

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches